Semaglutide
GLP-1 Receptor Agonist
Long-acting GLP-1 receptor agonist with a 168-hour half-life. Studied for glucose-dependent insulin secretion enhancement, gastric emptying delay, appetite suppression, and body composition improvements in metabolic research.
Format
5mg / vial
Purity
>99.5%
Category
Performance
Storage
2–8 °C
Research Price
€149
5mg / vial
RESEARCH USE ONLY
This compound is sold exclusively for in-vitro laboratory research. It is not intended for human consumption, therapeutic use, or self-administration. You must be 18+ and a qualified researcher to purchase.
Complete Your Research with the Pen Kit
Precise, painless, repeatable. The clinical-grade injection pen with 32G ultra-fine needles, bacteriostatic water, and your choice of peptide — ready to use out of the box.
€189
View details →Research Protocol Bundles
Metabolic Research Stack
Semaglutide + AOD-9604 + Fragment 176–191
A three-compound metabolic protocol combining GLP-1 receptor agonism (Semaglutide) with the two most studied lipolytic peptide fragments for body-composition research.
Bundle total
€297
10% bundle saving
Documented Research Parameters
Research Dose
0.25–2.4 mg per week (escalating)
Frequency
Once weekly
Duration
12–68 weeks (as per published clinical pharmacology)
Half-Life
~168 hours (7 days)
Route(s)
Subcutaneous
Solubility
Water
Reconstitution
2 ml bacteriostatic water per 5 mg vial
Key Research Findings
168-hour half-life achieved via albumin binding via C18 fatty diacid chain — enables once-weekly dosing in research models.
Crosses blood-brain barrier — central appetite suppression via ARC and hypothalamic GLP-1 receptors.
Demonstrated 14.9% body weight reduction in the STEP 1 trial — foundational reference data.
Reduces cardiovascular events — established in SELECT trial (2023), providing outcome data context.
Administration Reference
Subcutaneous administration is the only route studied for semaglutide in the pharmacological literature. Standard sites: abdomen (avoiding 2-inch radius around navel), outer thigh, upper arm. Weekly injection, rotating sites between administrations. Dose escalation — starting at 0.25 mg/week and increasing every 4 weeks — is the standard pharmacological approach to minimise GI effects in research subjects.
Documented Combination Protocols
Not typically combined — dual agonism study; compare efficacy differences in GIP+GLP-1 vs GLP-1 mono research.
Metabolic research stack: GLP-1 axis modulation combined with NAD+ dependent mitochondrial function.
Complementary AMPK and insulin sensitivity research across different signalling axes.
IMPORTANT RESEARCH DISCLAIMER
This compound is for in-vitro research and laboratory use only. It has not been evaluated or approved by any regulatory authority for human therapeutic use. It must not be used as a food, drug, or cosmetic. SYNTHEXA assumes no liability for misuse. Handle in accordance with Good Laboratory Practice.